We studied 24 male patients aged 26-62 years (median 41) prospectively presenting over a 5 year period with clinical features of hypogonadism and erectile dysfunction (ED), who had been treated with autologous or allogeneic bone marrow/stem cell transplant for a variety of haematological malignancies and had received either high-dose chemotherapy or high-dose chemotherapy combined with total body irradiation (TBI). Ten healthy adult controls (aged 35-50 years) were also studied. Erectile dysfunction (ED) was assessed clinically and by colour flow Doppler studies of the cavernosal vessels. Testicular function was assessed by testicular volume including orchidometry, FSH, LH and testosterone measurements. Libido and ejaculatory function were also recorded. Patients had severe hypogonadism as evidenced by low mean testicular volume (7.0 ؎ 2.4 ml vs 20 ؎ 2.0 ml; P Ͻ 0.001), elevated gonadotrophins (FSH = 18.54 ؎ 7.61 vs 5 IU/l (P Ͻ 0.001); LH = 8.02 ؎ 2.89 vs 3.9 IU/l (P Ͻ 0.001)) and low normal mean testosterone levels (16.4 nmol/l ؎ 9.1 vs 22.4 nmol/l (P Ͻ 0.5)). Cavernosal arterial insufficiency was found in 11/14 of TBI-treated and in 3/10 HDC-treated patients, indicative of vasculogenic damage to corpora cavernosal vessels. Patients were given a therapeutic trial with testosterone replacement therapy (TRT). Those who had diminished libido had a marked improvement in their symptoms but the effect of TRT on ED was equivocal. In conclusion, this is the first report to show vasculogenic insufficiency in patients with haematological malignancies treated by BMT. Although hypogonadism can account for diminished libido, arteriogenic insufficiency is likely to be an important factor accounting for ED in these patients, especially those treated by TBI. We recommend a comprehensive assessment including endocrine profile and colour flow Doppler study in formulating the best management plan in recipients of high-dose therapy presenting after transplant with ED. Keywords: high-dose chemotherapy; bone marrow transplantation; cavernosal arteriogenic insufficiency; erectile dysfunction
The long-term survival of recipients of high-dose chemotherapy (HDC) with or without total body irradiation (TBI) for haematological and non-haematological malignancies has risen dramatically in the last decade, yet little is known about the quality of life of the long-term survivors. Gonadal dysfunction is the most common long-term side-effect in the high-dose therapy and bone marrow transplantation (BMT) setting and is associated with significant morbidity. We 1 and others have shown germ cell damage 2 as well as Leydig cell insufficiency (low basal and HCG-stimulated testosterone levels) in such patients. 3 We have also shown that high-dose chemo-radiotherapy causes acute functional castration in patients with haematological malignancies within 72 h of TBI and there is a 50% loss of testicular volume. Subsequently patients may present with premature andropause. 1 Sexual dysfunction is a commonly recognised presentation in patients with adult hypogonadism and premature andropause. 4 Therefore, not surprisingly, many studies have reported a high incidence of sexual dysfunction in cancer patients which affects the quality of life of the survivors. 5 It is multifactorial in origin and factors other than hypogonadism may contribute to its complex aetiology. Psychogenic factors 1 including altered body image, loss of scalp and body hair, diminished testicular volume, generalised fatigue may all contribute. However, no information is available regarding the cavernosal vascular parameters in patients who had received BMT.
The aim of this study was to determine the cause of erectile dysfunction (ED) in recipients of HDC/TBI by using endocrine markers of testicular dysfunction and penile colour flow Doppler vascular parameters. Such information is important for formulation of the best treatment in the recipients of BMT presenting with erectile dysfunction and improve their quality of life.
Patients and methods
We studied 24 patients aged 26-62 (median 44) years who received a bone marrow/stem cell transplant and were con- ditioned with either high-dose chemotherapy (HDC) or high-dose chemotherapy combined with total body irradiation (TBI). This was a prospective study for 5 years and the patients had been referred to the Reproductive Medicine Unit of the University College London Hospital presenting with erectile dysfunction (ED) after transplantation. The mean duration of ED was 34 months (1-114 months). Seven patients had myeloma, 11 lymphoma (five NHL, six Hodgkin's disease), three acute myeloid leukaemia (AML), two acute lymphoblastic leukaemia (ALL) and one myelodysplastic syndrome (MDS). The conditioning was either BEAM (BCNU, etoposide, cytarabine, melphalan) or high-dose chemotherapy, (melphalan, cyclophosphamide or etoposide) combined with TBI. Twentyone patients received an autologous bone marrow/ peripheral blood stem cell transplant and three patients received an HLA-identical sibling marrow allograft. In the allogeneic setting, cyclosporin and methotrexate (MTX) were given for GVHD prophylaxis for two patients while one patient received in vivo/ex vivo depletion using CAM-PATH 1G/1M and no cyclosporin or methotrexate. The source of stem cells was peripheral blood for four patients and marrow for 20. All patients engrafted achieving neutrophil count above 0.5 × 10 9 /l on day 18 (11-27) and platelet count Ͼ20 × 10 9 /l on day 23 (10-37). The controls in our series were 10 healthy volunteers who were the partners of patients with unexplained infertility, being investigated in the routine infertile department and had normal endocrine 6 and testicular volumes 7 in accordance with our previously published data. 3 These people were used as controls for the endocrine parameters. Table 1 shows the clinical data including the haematological diagnosis of the patients.
The haemodynamic function of the penis can be evaluated by performing duplex sonography before and after injection of a vasoactive pharmacologic agent, such as papaverine or prostaglandin E1, to induce an erection. 8 After injection of one or both of these agents, the diameter of the cavernosal arteries and peak systolic velocity can be used to predict the presence of arterial cause of erectile dysfunction. 8, 9 It is not certain what cut-off between normal and abnormal blood flow must be used for the diagnosis of vasculogenic incompetence. Proposed values include 25, 30, 35 cm/s. 8 We defined mean peak systolic velocity (PSV) of Ͻ30 cm/s as an index of insufficient penile arterial blood flow. A clinical assessment of libido, grade of erectile dysfunction (0-III) and ejaculatory problems (absence of ejaculation, difficulty on ejaculatory performance, premature or small volume or painful ejaculation) were recorded at each visit by one observer (RC). Testicular volume was assessed by orchidometry 10 by the same observer (RC). Confirmation of testicular volume by ultrasound was recorded by the same observer (WL). Colour flow Doppler study involved use of papaverine followed by prostaglandin (PGE1). 11 This was done by a single observer (WL) with the patient in the recumbent position using a Hewlett Packard Sonos (Andover, MA, USA) 2500 scanner with a 7.5 mHZ mode imager and pulsed Doppler probe with real-time spectral analysis. The response to intracavernosal injection was graded (0-III); 0 = nil erection, I = tumescence only, II = partial rigidity, III = full rigidity. A peak systolic velocity Ͼ30 cm/s and an end diastolic velocity Ͻ5 cm/s were considered normal. Follicle stimulating hormone (FSH), luteinising hormone (LH) and testosterone (T) were assayed by the same observer (HHM) by using standard radioimmunoassay techniques using a double antibody method as described previously. 12 All samples were collected between 09.00 and 10.00 h to minimise diurnal variation. 13 In the course of management, patients with low or low-normal testosterone levels were offered testosterone replacement therapy (TRT) and their clinical and biochemical responses were recorded. The study was approved ethically by the committee of the University College London Hospitals NHS Trust.
Results and analysis

Endocrine data
Our study shows that as a group, patients had severe hypogonadism regardless of their treatment type, as evidenced by significantly low testicular volume compared with the controls (7.0 Ϯ 2.4 ml vs 20.0 Ϯ 2.0 ml (P Ͻ 0.001)). This was more marked in the TBI-treated group than in the HDC patients, and was indicative of more severe germ cell damage by radiotherapy (6.4 ml vs 7.9 ml). However, this difference was not statistically significant (P Ͻ 0.5). Similarly, the TBI group had more Leydig cell insufficiency as evidenced by low testosterone levels compared with the HDC group (13.4 Ϯ 2.3 vs 20.6 Ϯ 1.8 nmol/l (P Ͻ 0.001)). Although as a group the patients had a lower mean testosterone level than the controls (16.5 Ϯ 9.8 vs 22.4 Ϯ 2.8 nmol/l), this was within the normal reference range. FSH and LH levels were markedly higher in the patients than the controls (Table 2) indicative of testicular damage. Table 3 shows the erectile function of the patients at presentation. Two patients from each of the treatment group achieved grade III erection which was inadequate for full penetration.
Clinical and Doppler parameters for assessment of erectile dysfunction
Seventeen patients had diminished libido, 11 of whom Table 1 ). b Patients 1, 15, 22 (see Table 1 ). PSV = peak systolic velocity (cm/s). had a low-normal testosterone who responded to TRT. Seven had ejaculatory dysfunctions including premature ejaculation (n = 3), a reduced volume (n = 2), painful ejaculation (n = 1) and anejaculation (n = 1) ( Table 1) . Colour Doppler ultrasonography results are documented in Table 4 . 11/14 in the TBI group and 3/10 in the HDC group had arteriogenic insufficiency. Those patients who had vasculogenic insufficiency had more severe erectile dysfunction compared to those who had sufficient cavernosal vascular supply. All three patients in the HDC group who had vascular compromise (PSV Ͻ30 cm/s) had grade 0 (n = 1) or grade I ED (n = 2). Of the 11 patients in the TBI group who had PSV Ͻ30 cm/s had severe (grade I; n = 8) or moderate (grade II; n = 3) degree of ED.
Taken together, the data on endocrine and Doppler studies indicate that the aetiology of ED can be divided into three functional subsets: vasculogenic, hormonal and mixed (Table 5) .
Discussion
The psycho-social impact including interruption and difficulties in sexual function following BMT used for a number of malignancies, is becoming increasingly recognised. 14 The results of our study show that erectile dysfunction in recipients of HDC/TBI is multifactorial in origin, of which low testosterone level is only one factor. We have previously reported hypogonadism and Leydig cell insufficiency with premature andropause in recipients of BEAM autograft and also in TBI treated patients with leukaemia. 3 Other investigators have also shown evidence of hypogonadism after BMT. 2 Hypogonadism with low/low-normal testosterone levels was responsible for diminished libido as evidenced by complete correction of their sex drive following testosterone supplementation. This is in accordance with the well established physiological role of testosterone, in correction of target organ insufficiency and sex drive, including the placebo effect. 4 However, our patients had equivocal responses to their ED following a therapeutic trial of TRT and a large number of patients (78.5% of the TBI group and 33.3% of the HDC group) had cavernosal arteriogenic insufficiency. Taken together, our data indicate that an arteriogenic cause is probably an important contributor to the pathophysiology of erectile dysfunction, especially in patients treated with TBI.
Cavernosal arterial insufficiency has not been previously reported in BMT patients. However, this finding is not surprising because microangiopathy is a known delayed effect of radiation therapy. In fact, late microangiopathic complications consequent on TBI/radiotherapy are known to affect multiple organs. These include veno-occlusive disease of the liver, 15 microangiopathic nephropathy, 16 ophthalmopathy 17 and pneumonitis. 18 The mechanism of angiopathy involves intimal thickening, hyaline degeneration, periadventitial oedema and collagen deposition in the vessel wall. 19 Whether similar changes also occur in the cavernosal arteries remains to be elucidated. Also age-related degenerative changes may contribute to erectile dysfunction found in older men. 20 However a large proportion of our patients were young adults and there was only one patient over 60 years. Therefore age-related impotence seems to be unlikely to be the cardinal factor in the genesis of ED but it may act as a partial factor in older patients over 50 years.
The mixed aetiology of ED (endocrine and vasculogenic) is interesting and we recommend that recipients of HDC/TBI presenting with ED must have a full endocrine and colour Doppler work-up to define the aetiology accurately. Patients with diminished libido and low-normal testosterone levels may benefit from a therapeutic trial with TRT. In our longitudinal follow-up of 6-7 years, no serious effects have been observed in these patients. The effect of testosterone replacement therapy on prostatic cancer is still controversial. However, we appreciate that these patients having had one cancer are at a higher risk for the development of a second cancer. Therefore, we recommend serial monitoring of these patients with annual prostatic ultrasound, clinical examination and prostate-specific antigen assay to exclude prostatic hyperplasia. 21 The patients with arteriogenic insufficiency may benefit from a therapeutic trial with vasodilator or a smooth muscle relaxant. A therapeutic trial with 50-100 mg sildenafil in a small cohort of five patients was associated with a good response but the results are very preliminary for further evaluation.
In summary, erectile dysfunction due to vasculogenic insufficiency and hypogonadism is a common problem in recipients of HDC/TBI. Although not life-threatening, ED affects the quality of life of the survivors. A comprehensive work up may permit classification of the aetiology and correction of the disorder, thereby improving the quality of life of the patients.
